Evidence map›Paper›PMID 33138917›Full record

ArticleeLife2020

Mapping endothelial-cell diversity in cerebral cavernous malformations at single-cell resolution.

Fabrizio Orsenigo, Lei Liu Conze, Suvi Jauhiainen, Monica Corada, Francesca Lazzaroni, Matteo Malinverno, Veronica Sundell, Sara Isabel Cunha, Johan Brännström, Maria Ascención Globisch and 4 more

Open access · goldAbstract read
In one paragraph

Article in eLife, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
3.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 69 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. A Review of the Application of Spatial Transcriptomics in Neuroscience.Interdisciplinary sciences, computational life sciences · 2024
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 3 countries.

Fabrizio Orsenigo *Vascular Biology Unit, FIRC Institute of Molecular Oncology Foundation (IFOM), Milan, Italy.ORCID 0000-0001-9135-8478
Lei Liu Conze *Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Suvi JauhiainenDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Monica CoradaVascular Biology Unit, FIRC Institute of Molecular Oncology Foundation (IFOM), Milan, Italy.ORCID 0000-0001-8220-0871
Francesca LazzaroniVascular Biology Unit, FIRC Institute of Molecular Oncology Foundation (IFOM), Milan, Italy.ORCID 0000-0001-5767-7846
Matteo MalinvernoVascular Biology Unit, FIRC Institute of Molecular Oncology Foundation (IFOM), Milan, Italy.ORCID 0000-0001-8242-7937
Veronica SundellDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Sara Isabel CunhaDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Johan BrännströmDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Maria Ascención GlobischDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Claudio MadernaVascular Biology Unit, FIRC Institute of Molecular Oncology Foundation (IFOM), Milan, Italy.ORCID 0000-0002-1404-5408
Maria Grazia LampugnaniVascular Biology Unit, FIRC Institute of Molecular Oncology Foundation (IFOM), Milan, Italy.ORCID 0000-0002-4802-7064
Peetra Ulrica MagnussonDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.ORCID 0000-0003-1142-854X
Elisabetta DejanaVascular Biology Unit, FIRC Institute of Molecular Oncology Foundation (IFOM), Milan, Italy.ORCID 0000-0002-0007-0426
Uppsala University · SEIFOM · ITMario Negri Institute for Pharmacological Research · IT

Funding

Agenzia Italiana del Farmaco, Ministero della Salute AIFA-2016-02364593Associazione Italiana per la Ricerca sul Cancro 5x1000 MYNERVA AIRC 21267Associazione Italiana per la Ricerca sul Cancro AIRC IG 23223Fondazione Telethon GGP19202H2020 European Research Council 74292H2020 Marie Skłodowska-Curie Actions 675619Knut och Alice Wallenbergs Stiftelse 2015-0030Vetenskapsrådet 2013-9279
6 · The paper itself

Abstract

Cerebral cavernous malformation (CCM) is a rare neurovascular disease that is characterized by enlarged and irregular blood vessels that often lead to cerebral hemorrhage. Loss-of-function mutations to any of three genes results in CCM lesion formation; namely,

Indexed as

AnimalsApoptosis Regulatory ProteinsArteriesBrainCell DifferentiationDisease Models, AnimalEndothelial CellsGene DeletionHemangioma, Cavernous, Central Nervous SystemImmunohistochemistryMiceMice, Inbred C57BLMicroscopy, ConfocalMitosisNeovascularization, PathologicPhenotypeApoptosis Regulatory ProteinsPDCD10 protein, mouseTamoxifenblood brain barriercell biologycerebral cavernous malformationgeneticsgenomicsmousesingle cell RNA sequencingspatial transcriptomicsvascular biologyvascular disease

Identifiers

PMID33138917
PMCPMC7609066
OpenAlexW3097937851

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.